Knowthestock.com
MRK - Merck & Co Inc
SNP 500DOW 30

Buy

Strong Growth and ImprovingStock Price Attractive
WeakStrong
WeakStrong

66%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 30.21%
Operating Income Growth is 326.08%
Net Income Growth is 197.59%
Earnings Per Share (EPS) Growth is 313.29%
Net Margin is 29.0%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.39
Debt Ratio is 0.3
Current Debt to Net Income Ratio is 0.76
Total Debt to Total Assets Ratio is 0.3
Cash Flow is STRONG
Cash from Operations Growth is 130.54%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Merck & Co Inc (MRK) - www.merck.com
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.
Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Kenneth Frazier
Employees - 2,021
    Close

    Login/Register

    Home


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2022 and future.